Psilocybin-Assisted Therapy for Depression
This study is exploring psilocybin-assisted therapy (PAT) as a potential treatment for depression. Researchers are giving participants a 25 mg capsule of synthetic psilocybin (Usona Institute) to see how it affects their depression symptoms and psychological flexibility. The study aims to understand both the short-term (about 1 week after treatment) and longer-term (about 30 days after treatment) effects. You might be able to join if you are over 18, have been diagnosed with depression, and meet other health requirements. The study plans to enroll 50 participants. The current recruitment status is unclear.
- Study design
- This is an interventional study planning to enroll 50 participants. The phase of the study is not specified.
- What's involved
- Participants will receive psilocybin and undergo MRI scans and other biological measures before, during, and after treatment. Depression symptoms and psychological flexibility will be measured at 1 week and 30 days post-dose.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for about 30 days after each administration session to assess persisting effects.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Psilocybin-Assisted Therapy as a Treatment for Depression
At a glance
Conditions
NCT07582120
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Washington University School of Medicine
St Louis, Missouristudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Characterize ACUTE (~1 week post-dose) and PERSISTING (~30 days post-dose) effects of PAT in depressed adults at two possible administrations on depression symptom severity using the Montgomery-Asberg Depression Rating Scale (MADRS) score.1 week and 30 days post-dose for both administration sessions
The MADRS is a 10-item instrument used to assess depression severity. The total MADRS score ranges from 0-60, with higher scores indicating increased severity of depression
- Characterize ACUTE (~1 week post-dose) and PERSISTING (~30 days post-dose) effects of PAT in depressed adults at two possible administrations on psychological flexibility using the Multidimensional Psychological Flexibility Inventory (MPFI).1 week and 30 days post-dose for both administration sessions
The Multidimensional Psychological Flexibility Inventory (MPFI) is scored by averaging 60 items (or 24 in the short form) on a 1-6 scale (1 = "never true", 6 = "always true"). Higher average scores (1-6) indicate higher levels of the trait, with 12 subscales mapping onto psychological flexibility and inflexibility, allowing for detailed, sub-process, or global profiling.